Log in
NASDAQ:ADAP

Adaptimmune Therapeutics Competitors

$4.80
+0.50 (+11.63 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.29
Now: $4.80
$5.16
50-Day Range
$4.30
MA: $8.07
$10.78
52-Week Range
$0.71
Now: $4.80
$13.40
Volume3.78 million shs
Average Volume1.14 million shs
Market Capitalization$624.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13

Competitors

Adaptimmune Therapeutics (NASDAQ:ADAP) Vs. SRNE, EDIT, BEAM, REPL, SGMO, and CRTX

Should you be buying ADAP stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Adaptimmune Therapeutics, including Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Beam Therapeutics (BEAM), Replimune Group (REPL), Sangamo Therapeutics (SGMO), and Cortexyme (CRTX).

Adaptimmune Therapeutics (NASDAQ:ADAP) and Sorrento Therapeutics (NASDAQ:SRNE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

98.6% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 24.1% of Sorrento Therapeutics shares are held by institutional investors. 18.9% of Adaptimmune Therapeutics shares are held by company insiders. Comparatively, 3.4% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Adaptimmune Therapeutics and Sorrento Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptimmune Therapeutics$1.12 million557.61$-137,160,000.00($1.32)-3.64
Sorrento Therapeutics$31.43 million67.29$-292,070,000.00($2.12)-3.81

Adaptimmune Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Adaptimmune Therapeutics and Sorrento Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptimmune Therapeutics03302.50
Sorrento Therapeutics00203.00

Adaptimmune Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 243.75%. Sorrento Therapeutics has a consensus price target of $27.00, indicating a potential upside of 234.16%. Given Adaptimmune Therapeutics' higher possible upside, research analysts clearly believe Adaptimmune Therapeutics is more favorable than Sorrento Therapeutics.

Risk & Volatility

Adaptimmune Therapeutics has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.61, meaning that its share price is 161% more volatile than the S&P 500.

Profitability

This table compares Adaptimmune Therapeutics and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptimmune Therapeutics-5,687.30%-58.60%-42.69%
Sorrento Therapeutics-760.19%-490.67%-38.31%

Summary

Adaptimmune Therapeutics beats Sorrento Therapeutics on 9 of the 14 factors compared between the two stocks.

Adaptimmune Therapeutics (NASDAQ:ADAP) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Valuation & Earnings

This table compares Adaptimmune Therapeutics and Editas Medicine's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptimmune Therapeutics$1.12 million557.61$-137,160,000.00($1.32)-3.64
Editas Medicine$20.53 million99.37$-133,750,000.00($2.68)-12.22

Editas Medicine has higher revenue and earnings than Adaptimmune Therapeutics. Editas Medicine is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

98.6% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Editas Medicine shares are held by institutional investors. 18.9% of Adaptimmune Therapeutics shares are held by company insiders. Comparatively, 0.9% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Adaptimmune Therapeutics has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Adaptimmune Therapeutics and Editas Medicine, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptimmune Therapeutics03302.50
Editas Medicine04302.43

Adaptimmune Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 243.75%. Editas Medicine has a consensus price target of $44.80, indicating a potential upside of 36.75%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Adaptimmune Therapeutics is more favorable than Editas Medicine.

Profitability

This table compares Adaptimmune Therapeutics and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptimmune Therapeutics-5,687.30%-58.60%-42.69%
Editas Medicine-404.88%-46.57%-26.36%

Summary

Adaptimmune Therapeutics beats Editas Medicine on 8 of the 13 factors compared between the two stocks.

Beam Therapeutics (NASDAQ:BEAM) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Beam Therapeutics and Adaptimmune Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$20,000.0098,002.49$-78,330,000.00($14.05)-2.70
Adaptimmune Therapeutics$1.12 million557.61$-137,160,000.00($1.32)-3.64

Beam Therapeutics has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

52.5% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 98.6% of Adaptimmune Therapeutics shares are owned by institutional investors. 0.7% of Beam Therapeutics shares are owned by insiders. Comparatively, 18.9% of Adaptimmune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Beam Therapeutics and Adaptimmune Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Beam Therapeutics00203.00
Adaptimmune Therapeutics03302.50

Beam Therapeutics currently has a consensus target price of $33.00, indicating a potential downside of 12.91%. Adaptimmune Therapeutics has a consensus target price of $16.50, indicating a potential upside of 243.75%. Given Adaptimmune Therapeutics' higher probable upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Beam Therapeutics.

Profitability

This table compares Beam Therapeutics and Adaptimmune Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Beam TherapeuticsN/AN/AN/A
Adaptimmune Therapeutics-5,687.30%-58.60%-42.69%

Summary

Beam Therapeutics beats Adaptimmune Therapeutics on 7 of the 13 factors compared between the two stocks.

Replimune Group (NASDAQ:REPL) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Analyst Ratings

This is a breakdown of current recommendations for Replimune Group and Adaptimmune Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Replimune Group00703.00
Adaptimmune Therapeutics03302.50

Replimune Group currently has a consensus target price of $44.2143, indicating a potential downside of 2.18%. Adaptimmune Therapeutics has a consensus target price of $16.50, indicating a potential upside of 243.75%. Given Adaptimmune Therapeutics' higher probable upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Replimune Group.

Valuation & Earnings

This table compares Replimune Group and Adaptimmune Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A$-52,630,000.00($1.54)-29.35
Adaptimmune Therapeutics$1.12 million557.61$-137,160,000.00($1.32)-3.64

Replimune Group has higher earnings, but lower revenue than Adaptimmune Therapeutics. Replimune Group is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Replimune Group and Adaptimmune Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Replimune GroupN/A-31.09%-25.11%
Adaptimmune Therapeutics-5,687.30%-58.60%-42.69%

Risk & Volatility

Replimune Group has a beta of 3.23, indicating that its share price is 223% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500.

Insider and Institutional Ownership

60.9% of Replimune Group shares are owned by institutional investors. Comparatively, 98.6% of Adaptimmune Therapeutics shares are owned by institutional investors. 50.9% of Replimune Group shares are owned by insiders. Comparatively, 18.9% of Adaptimmune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Replimune Group beats Adaptimmune Therapeutics on 8 of the 13 factors compared between the two stocks.

Adaptimmune Therapeutics (NASDAQ:ADAP) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Adaptimmune Therapeutics and Sangamo Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptimmune Therapeutics03302.50
Sangamo Therapeutics01502.83

Adaptimmune Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 243.75%. Sangamo Therapeutics has a consensus price target of $16.25, indicating a potential upside of 49.91%. Given Adaptimmune Therapeutics' higher probable upside, equities analysts clearly believe Adaptimmune Therapeutics is more favorable than Sangamo Therapeutics.

Earnings & Valuation

This table compares Adaptimmune Therapeutics and Sangamo Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptimmune Therapeutics$1.12 million557.61$-137,160,000.00($1.32)-3.64
Sangamo Therapeutics$102.43 million14.92$-95,190,000.00($0.85)-12.75

Sangamo Therapeutics has higher revenue and earnings than Adaptimmune Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Adaptimmune Therapeutics and Sangamo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptimmune Therapeutics-5,687.30%-58.60%-42.69%
Sangamo Therapeutics-91.17%-23.12%-14.74%

Risk and Volatility

Adaptimmune Therapeutics has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500.

Insider and Institutional Ownership

98.6% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 54.5% of Sangamo Therapeutics shares are owned by institutional investors. 18.9% of Adaptimmune Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Sangamo Therapeutics beats Adaptimmune Therapeutics on 8 of the 13 factors compared between the two stocks.

Adaptimmune Therapeutics (NASDAQ:ADAP) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Adaptimmune Therapeutics and Cortexyme, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptimmune Therapeutics03302.50
Cortexyme00403.00

Adaptimmune Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 243.75%. Cortexyme has a consensus price target of $68.3333, indicating a potential upside of 37.24%. Given Adaptimmune Therapeutics' higher probable upside, equities analysts clearly believe Adaptimmune Therapeutics is more favorable than Cortexyme.

Earnings & Valuation

This table compares Adaptimmune Therapeutics and Cortexyme's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptimmune Therapeutics$1.12 million557.61$-137,160,000.00($1.32)-3.64
CortexymeN/AN/A$-36,980,000.00($1.94)-25.66

Cortexyme has lower revenue, but higher earnings than Adaptimmune Therapeutics. Cortexyme is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Adaptimmune Therapeutics and Cortexyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptimmune Therapeutics-5,687.30%-58.60%-42.69%
CortexymeN/A-34.24%-32.21%

Risk and Volatility

Adaptimmune Therapeutics has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.

Insider and Institutional Ownership

98.6% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 51.7% of Cortexyme shares are owned by institutional investors. 18.9% of Adaptimmune Therapeutics shares are owned by company insiders. Comparatively, 19.8% of Cortexyme shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cortexyme beats Adaptimmune Therapeutics on 7 of the 13 factors compared between the two stocks.


Adaptimmune Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.08+2.5%$2.11 billion$31.43 million-4.96Analyst Downgrade
Editas Medicine logo
EDIT
Editas Medicine
1.3$32.76+1.5%$2.04 billion$20.53 million-13.00Heavy News Reporting
BEAM
Beam Therapeutics
1.0$37.89+6.3%$1.96 billion$20,000.00-2.70Heavy News Reporting
Replimune Group logo
REPL
Replimune Group
1.4$45.20+4.0%$1.82 billionN/A-27.23Analyst Upgrade
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$10.84+1.8%$1.53 billion$102.43 million-13.06
CRTX
Cortexyme
1.4$49.79+1.9%$1.47 billionN/A-24.41
NanoString Technologies logo
NSTG
NanoString Technologies
0.9$36.12+1.5%$1.37 billion$125.57 million-20.18High Trading Volume
Mesoblast logo
MESO
Mesoblast
1.4$11.21+0.4%$1.32 billion$32.16 million-15.36Analyst Downgrade
Increase in Short Interest
Coherus Biosciences logo
CHRS
Coherus Biosciences
1.4$17.59+3.4%$1.26 billion$356.07 million7.52Analyst Downgrade
Heavy News Reporting
BDTX
I-Mab
1.4$31.86+3.8%$1.14 billionN/A-1.88Insider Selling
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$14.61+0.3%$1.09 billionN/A-2.92Heavy News Reporting
REGENXBIO logo
RGNX
REGENXBIO
1.6$28.86+1.2%$1.08 billion$35.23 million-7.91
TBIO
Translate Bio
1.3$14.03+3.1%$1.04 billion$7.80 million-8.20
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.8$12.36+0.6%$996.96 million$250,000.00-10.21Increase in Short Interest
Compugen logo
CGEN
Compugen
1.4$14.16+0.8%$968.83 million$17.80 million-37.26Analyst Downgrade
Krystal Biotech logo
KRYS
Krystal Biotech
1.4$48.15+1.8%$946.82 millionN/A-38.83
Vericel logo
VCEL
Vericel
1.7$20.75+2.7%$938.94 million$117.85 million-2,075.00Analyst Revision
Nantkwest logo
NK
Nantkwest
1.4$8.58+6.3%$926.38 million$40,000.00-12.08Analyst Downgrade
Heavy News Reporting
Cellectis logo
CLLS
Cellectis
1.2$19.41+8.0%$824.65 million$22.99 million-12.52Analyst Downgrade
Heavy News Reporting
PASG
Passage Bio
1.6$17.06+0.3%$776.01 millionN/A0.00
ALEC
Alector
1.4$9.49+0.1%$752.18 million$21.22 million-4.67Analyst Upgrade
Heavy News Reporting
Agenus logo
AGEN
Agenus
1.5$3.94+3.6%$722.75 million$150.05 million-3.46Upcoming Earnings
TCRR
Tcr2 Therapeutics
1.6$20.89+9.0%$696.47 millionN/A-8.56Heavy News Reporting
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
2.1$3.71+3.5%$655.08 million$48.83 million-4.42Heavy News Reporting
Vaxart logo
VXRT
Vaxart
1.3$5.64+3.4%$617.41 million$9.86 million-9.56Analyst Upgrade
AVROBIO logo
AVRO
AVROBIO
1.6$16.68+1.1%$607.82 millionN/A-5.83
OYST
Oyster Point Pharma
1.6$21.39+4.2%$550.86 millionN/A-1.96
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$12.01+2.2%$540.21 million$2.91 million-4.35Analyst Downgrade
Heavy News Reporting
MeiraGTx logo
MGTX
MeiraGTx
1.5$13.32+1.7%$497.64 million$13.29 million-8.65Analyst Downgrade
Heavy News Reporting
Proteon Therapeutics logo
PRTO
Proteon Therapeutics
0.8$21.48+0.3%$476.41 millionN/A-18.68Upcoming Earnings
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.6$9.91+2.3%$460.91 million$69.89 million-2.24Analyst Downgrade
Analyst Revision
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.10+12.2%$453.08 millionN/A-8.36Analyst Report
High Trading Volume
Analyst Revision
Sutro Biopharma logo
STRO
Sutro Biopharma
1.4$12.30+2.8%$441.32 million$42.74 million-11.18Heavy News Reporting
ORTX
Orchard Therapeutics
1.5$4.52+5.5%$439.62 million$2.51 million-2.47Unusual Options Activity
Scholar Rock logo
SRRK
Scholar Rock
1.4$14.14+2.1%$422.50 million$20.49 million-6.52Heavy News Reporting
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.4$11.03+0.1%$412.85 million$104.39 million-6.73
HARP
Harpoon Therapeutics
2.1$15.34+2.1%$385.68 million$5.78 million-6.82Analyst Upgrade
Surface Oncology logo
SURF
Surface Oncology
1.2$9.57+7.7%$381.94 million$15.36 million-10.88Heavy News Reporting
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$4.59+2.0%$370.73 millionN/A-2.07Analyst Downgrade
Heavy News Reporting
PRVL
Prevail Therapeutics
1.6$10.82+6.4%$370.26 millionN/A-4.57Analyst Upgrade
Heavy News Reporting
IPHA
Innate Pharma
1.2$4.67+15.2%$368.84 million$96.12 million-13.74High Trading Volume
Heavy News Reporting
DTIL
Precision BioSciences
1.6$6.98+1.9%$365.37 million$22.24 million-3.64Analyst Downgrade
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.7$18.41+0.1%$357.76 million$340,000.00-6.65Analyst Upgrade
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$10.75+5.2%$339.38 millionN/A-10.24Analyst Downgrade
Heavy News Reporting
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
2.0$9.49+0.6%$323.31 million$147.87 million15.31
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
2.0$10.09+1.3%$295.06 millionN/A-3.78Analyst Downgrade
CABA
Cabaletta Bio
1.4$12.06+3.9%$289.92 millionN/A-2.96Heavy News Reporting
PDL BioPharma logo
PDLI
PDL BioPharma
2.0$2.26+3.1%$257.60 million$54.76 million-1.70
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
2.0$9.87+1.7%$252.28 million$20,000.000.00
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.3$1.77+9.6%$219.37 million$4.13 million-4.32Analyst Report
High Trading Volume
Heavy News Reporting
This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.